Health
Eli Lilly’s Oral Pill Shows Strong Weight Loss Results in Clinical Trials
Eli Lilly’s new oral pill, orforglipron, has demonstrated up to 8% weight loss in clinical trials, outperforming existing oral semaglutide alternatives. The results signal growing competition in the weight-loss drug market, where demand for convenient and effective treatments continues to rise.
The trial, published in The Lancet, involved more than 1,600 participants with type 2 diabetes across over 130 research centres in five countries. Participants were assigned to different doses of orforglipron, ranging from 12mg to 36mg, or equivalent doses of oral semaglutide for one year.
Results showed that roughly 60% of those taking orforglipron lost at least 5% of their body weight, compared with 40% of participants on semaglutide. Between 28% and 44% of patients on orforglipron lost 10% or more, while only 13% to 21% of those on semaglutide reached similar reductions. Participants also experienced improved blood sugar control, with orforglipron lowering glucose levels more effectively than its competitor.
Experts welcomed the results but urged caution. Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, said oral medications that help patients lose weight and maintain it are vital, noting that excess weight is a key driver of type 2 diabetes and associated cardiovascular risks. Marie Spreckley, a weight management researcher at Cambridge University, highlighted that while the trial showed benefits, side effects and long-term safety remain important considerations.
Adverse effects were more common among orforglipron users. Approximately 9-10% of participants stopped the treatment due to gastrointestinal issues, compared with about 5% of those on semaglutide. Spreckley noted that these effects could affect real-world tolerability outside the trial environment and called for further research on long-term outcomes, including cardiovascular health and sustained effectiveness.
Orforglipron is designed as a daily pill that does not require food or water restrictions, offering a more convenient alternative to injectable treatments such as Ozempic, Wegovy, and Mounjaro. Eli Lilly, which also markets Zepbound and Mounjaro, is positioning orforglipron as a competitor to Novo Nordisk, the current provider of the only approved oral GLP-1 pill.
The pill is under review by the US Food and Drug Administration. If approved, Eli Lilly said US patients with obesity could access the drug starting at $149 (€125.92) for the lowest dose, with higher doses priced up to $399 (€337) if insurance does not cover the cost.
As pharmaceutical companies race to make weight-loss treatments more accessible, orforglipron’s strong results highlight the potential of oral GLP-1 therapies to reshape the market, even as questions about side effects and long-term safety remain.
-
Entertainment2 years agoMeta Acquires Tilda Swinton VR Doc ‘Impulse: Playing With Reality’
-
Business2 years agoSaudi Arabia’s Model for Sustainable Aviation Practices
-
Business2 years agoRecent Developments in Small Business Taxes
-
Sports2 years agoChina’s Historic Olympic Victory Sparks National Pride Amid Controversy
-
Home Improvement1 year agoEffective Drain Cleaning: A Key to a Healthy Plumbing System
-
Politics2 years agoWho was Ebrahim Raisi and his status in Iranian Politics?
-
Sports2 years agoKeely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m
-
Business2 years agoCarrectly: Revolutionizing Car Care in Chicago
